Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank™ in Treatment of Diabetic Foot Osteomyelitis

March 10, 2021

Press Releases

Comments Off on Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank™ in Treatment of Diabetic Foot Osteomyelitis

GAITHERSBURG, MD, March 10, 2021 – Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to advancing therapies that address the global rise of multi-drug resistant infections, announced today that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for PhageBank™ phage therapy for the treatment of Diabetic Foot Osteomyelitis (DFO). “Advancing […]

Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank™ for the Treatment of Prosthetic Joint Infections

February 10, 2021

Press Releases

Comments Off on Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank™ for the Treatment of Prosthetic Joint Infections

– Phase 1/2 trial to be conducted at Mayo Clinic in Rochester, Minnesota, starting Q2 2021 – GAITHERSBURG, MD, February 10, 2021 – Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat the global rise of bacterial and viral infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) […]

Adaptive Phage Therapeutics to Participate in the NobleCon17 Virtual Investor Conference

January 15, 2021

Press Releases

Comments Off on Adaptive Phage Therapeutics to Participate in the NobleCon17 Virtual Investor Conference

GAITHERSBURG, MD, January 15, 2021 – Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the company will participate in the 17th Annual Small & Microcap Investor Conference (NobleCon17) being organized by Noble Financial Group, taking place virtually on January 19-20, 2021. Chief Executive Officer, Greg Merril, […]

FDA Clears Expanded Access IND for APT’s PhageBank™ Therapy to Combat COVID-19-related Bacterial Infections

November 18, 2020

Press Releases

Comments Off on FDA Clears Expanded Access IND for APT’s PhageBank™ Therapy to Combat COVID-19-related Bacterial Infections

A significant increase in mortality has been seen in COVID-19 patients with antibiotic resistant bacterial infections. APT has made available therapeutic phage treatment to physicians in the Rio Grande Valley of Texas who are treating COVID-19 patients with secondary Carbapenem Resistant Acinetobacter baumannii (CRAB) on an emergency basis Now the FDA has granted APT an Expanded […]

PhageBank™ Deployed in Texas Outbreak of Life-Threatening Carbapenem Resistant A. baumannii (CRAB) in COVID-19 Patients

November 2, 2020

Press Releases

Comments Off on PhageBank™ Deployed in Texas Outbreak of Life-Threatening Carbapenem Resistant A. baumannii (CRAB) in COVID-19 Patients

November 02, 2020 11:00 AM Eastern Standard Time Eight COVID-19 + CRAB patients have received PhageBank™ therapy under FDA-approved emergency allowance, with more anticipated Significant increased mortality has been observed from secondary CRAB infections in COVID-19 patients APT and its partners are currently self-funding emergency use of PhageBank™ in this patient group, and are seeking […]

Adaptive Phage Therapeutics Receives Orphan Drug Designation

October 29, 2020

News

Comments Off on Adaptive Phage Therapeutics Receives Orphan Drug Designation

Adaptive Phage Therapeutics (APT), announced the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for the treatment of prosthetic joint infections (PJI) utilizing PhageBank™.  Orphan drug designation is given to drugs and biologics being developed to treat rare medical conditions, specifically those affecting fewer than 200,000 persons in the U.S. Orphan […]

Adaptive Phage Therapeutics Receives Orphan Drug Designation for PhageBank™ in Prosthetic Joint Infections

October 22, 2020

Press Releases

Comments Off on Adaptive Phage Therapeutics Receives Orphan Drug Designation for PhageBank™ in Prosthetic Joint Infections

October 22, 2020 11:00 AM Eastern Daylight Time GAITHERSBURG, MD–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat the global rise of multi-drug resistant infectious diseases, today announced the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for the treatment of prosthetic joint infections […]

APT named 2020 Emerging Life Science Company of the Year

October 16, 2020

News

Comments Off on APT named 2020 Emerging Life Science Company of the Year

The Maryland Tech Council (MTC), Maryland’s largest technology and life sciences trade association, announced the winners of its 32nd Annual Industry Awards. Due to COVID-19, the association pivoted to a virtual live broadcast to announce winners for the first time in the organization’s history.

Adaptive Phage Therapeutics Receives Department of Defense Award for Development of COVID-19 Vaccine

August 20, 2020

Press Releases

Comments Off on Adaptive Phage Therapeutics Receives Department of Defense Award for Development of COVID-19 Vaccine

August 20, 2020 11:09 AM Eastern Daylight Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat the global rise of bacterial and viral infectious diseases, today announced the Department of Defense (DoD) awarded APT $9.8 million for research development of multiple high-priority, bacteriophage-based display vaccine candidates against the novel coronavirus […]

APT Receives DoD Award for Development of COVID-19 Vaccine

August 19, 2020

News

Comments Off on APT Receives DoD Award for Development of COVID-19 Vaccine

GAITHERSBURG, Md., August 19, 2020 – Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat the global rise of bacterial and viral infectious diseases, today announced the Department of Defense (DoD) awarded APT $9.8 million for research development of multiple high-priority, bacteriophage-based display vaccine candidates against the novel coronavirus (SARS-CoV-2). The effort will advance and evaluate […]